[Sequential diagnostic procedure in the evaluation of the tumoritropic properties of radiopharmaceuticals].

The optimum value of diagnostic procedure in the assessment of RP tumoritrophism (99mTc-pyrophosphate) was shown. The results of radionuclide studies using 99mTc-pyrophosphate in 193 patients with bone pathology were cited by way of example. Diagnostic thresholds with error levels were established. The diagnostic criteria (sensitivity, specificity, accuracy, etc.) were established proceeding from the criteria of malignant and benign features. Some differential-diagnostic potentialities of 99mTc-pyrophosphate in the recognition of certain groups of bone pathology were revealed.